84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]夏天衛(wèi),李若頎,環(huán)大維,等.基于網(wǎng)絡(luò)藥理學(xué)方法探究補(bǔ)腎活血湯治療激素性股骨頭壞死的作用機(jī)制[J].中醫(yī)正骨,2020,32(03):14-20.
　XIA Tianwei,LI Ruoqi,HUAN Dawei,et al.A study of mechanism of action of Bushen Huoxue Tang(補(bǔ)腎活血湯)for treatment of steroid-induced osteonecrosis of the femoral head using network pharmacology approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2020,32(03):14-20.
點(diǎn)擊復(fù)制

基于網(wǎng)絡(luò)藥理學(xué)方法探究補(bǔ)腎活血湯治療激素性股骨頭壞死的作用機(jī)制()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第32卷
期數(shù):
2020年03期
頁(yè)碼:
14-20
欄目:
基礎(chǔ)研究
出版日期:
2020-03-20

文章信息/Info

Title:
A study of mechanism of action of Bushen Huoxue Tang(補(bǔ)腎活血湯)for treatment of steroid-induced osteonecrosis of the femoral head using network pharmacology approach
作者:
夏天衛(wèi)1; 李若頎2; 環(huán)大維2; 李泰賢3; 石佳勇2; 高潤(rùn)子2; 沈計(jì)榮1
(1.江蘇省中醫(yī)院,江蘇 南京 210019; 2.南京中醫(yī)藥大學(xué),江蘇 南京 210023; 3.中國(guó)中醫(yī)科學(xué)院中藥研究所,北京 100700)
Author(s):
XIA Tianwei1; LI Ruoqi2; HUAN Dawei2; LI Taixian3; SHI Jiayong2; GAO Runzi2; SHEN Jirong1
1.Jiangsu Provincial Hospital of Traditional Chinese Medicine,Nanjing 210019,Jiangsu,China 2.Nanjing University of Traditional Chinese Medicine,Nanjing 210023,Jiangsu,China 3.Institute of Chinese Materia Medica of China Academy of Chinese Medical Sciences,Beijing 100700,China
關(guān)鍵詞:
股骨頭壞死;  補(bǔ)腎活血湯;  藥理作用分子作用機(jī)制;  信號(hào)通路;  網(wǎng)絡(luò)藥理學(xué)
Keywords:
femur head necrosis;  Bushen Huoxue Tang;  molecular mechanisms of pharmacologic action;  signaling pathway;  network pharmacology
摘要:
目的:探討補(bǔ)腎活血湯治療激素性股骨頭壞死(steroid-induced osteonecrosis of the femoral head,SONFH)的作用機(jī)制。方法:通過(guò)中醫(yī)藥整合藥理學(xué)網(wǎng)絡(luò)計(jì)算研究平臺(tái)(integrative pharmacology-based network computational research platform of Traditional Chinese Medicine,TCMIP)v2.0預(yù)測(cè)、篩選補(bǔ)腎活血湯組方中14味中藥的作用靶標(biāo),通過(guò)GeneCards、CTD和OMIM數(shù)據(jù)庫(kù)查詢(xún)SONFH的疾病靶點(diǎn)。根據(jù)獲取的藥物靶標(biāo)和疾病靶點(diǎn),進(jìn)一步利用TCMIP v2.0中醫(yī)藥關(guān)聯(lián)網(wǎng)絡(luò)分析模塊構(gòu)建“藥物靶標(biāo)-疾病靶點(diǎn)”相互作用網(wǎng)絡(luò),根據(jù)網(wǎng)絡(luò)拓?fù)涮卣髦岛Y選補(bǔ)腎活血湯治療SONFH的核心作用靶點(diǎn)。利用GO和KEGG數(shù)據(jù)庫(kù),采用富集算法挖掘上述方劑核心作用靶點(diǎn)的生物學(xué)功能和通路信息。結(jié)果:共獲得891個(gè)補(bǔ)腎活血湯藥物靶標(biāo)和365個(gè)SONFH疾病靶點(diǎn)。經(jīng)“藥物靶標(biāo)-疾病靶點(diǎn)”相互作用網(wǎng)絡(luò)分析,最終篩選出31個(gè)補(bǔ)腎活血湯治療SONFH核心靶點(diǎn),GO功能分析富集出生物過(guò)程532條、分子功能29條,KEGG信號(hào)通路富集分析出相關(guān)通路共12條,主要涉及炎癥免疫調(diào)節(jié)(chemokine signaling pathway,Toll-like receptor signaling pathway,NOD-like receptor signaling pathway,leukocyte transendothelial migration,Complement and coagulation cascades,cytokine-cytokine receptor interaction)、血管新生及血液循環(huán)調(diào)節(jié)(VEGF signaling pathway)、神經(jīng)系統(tǒng)調(diào)節(jié)(neuroactive ligand-receptor interaction)和細(xì)胞功能調(diào)節(jié)(apoptosis,regulation of actin cytoskeleton)等方面。結(jié)論:結(jié)合SONFH的病理機(jī)制,排除缺乏特異性的信號(hào)通路,我們推測(cè)補(bǔ)腎活血湯可能通過(guò)調(diào)節(jié)TLR4/NF-κB和VEGF信號(hào)通路發(fā)揮補(bǔ)腎壯骨、活血化瘀的功效,這可能是其治療SONFH的作用機(jī)制之一。
Abstract:
Objective:To explore the mechanism of action of Bushen Huoxue Tang(補(bǔ)腎活血湯,BSHXT)for treatment of steroid-induced osteonecrosis of the femoral head(SONFH).Methods:Fourteen Traditional Chinese Medicines(TCMs)in BSHXT prescription were screened for predicting their therapeutic targets by searching integrative pharmacology-based network computational research platform of Traditional Chinese Medicine(TCMIP)v2.0,and the pathogenic targets of SONFH were searched from GeneCards,CTD and OMIM databases.The network of interaction between drug targets and disease targets was built by using TCM association network analysis module of TCMIP v2.0 according to the obtained drug targets and pathogenic targets,and the core therapeutic targets of BSHXT for treatment of SONFH were selected according to network topology eigenvalues.The biological function and pathway information of core therapeutic targets of BSHXT were found out from Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)databases by using enrichment algorithm.Results:Eight hundred and ninety-one therapeutic targets of BSHXT and 365 pathogenic targets of SONFH were obtained.Thirty-one core targets of BSHXT for treatment of SONFH were selected out finally through analyzing the network of interaction between drug targets and pathogenic targets.The results of GO enrichment analysis demonstrated 532 pieces of information about biological processes and 29 pieces of information about molecular function and the results of KEGG enrichment analysis demonstrated 12 signal pathways,which related to inflammatory-immune regulation(chemokine signaling pathway,Toll-like receptor signaling pathway,NOD-like receptor signaling pathway,leukocyte transendothelial migration,Complement and coagulation cascades,cytokine-cytokine receptor interaction),angiogenesis and blood circulation regulation(VEGF signaling pathway),nervous system regulation(neuroactive ligand-receptor interaction)and cell function regulation(apoptosis,regulation of actin cytoskeleton).Conclusion:After ruling out nonspecific signaling pathways according to the pathological mechanism of SONFH,we can infer that BSHXT may produce the effect of reinforcing kidney and strengthening bone and activating blood and resolving stasis through regulating TLR4/NF-κB and VEGF signal pathways,which may be one of its mechanisms of action in treatment of SONFH.

參考文獻(xiàn)/References:

[1] 中華老年骨科與康復(fù)電子雜志編輯委員會(huì).股骨頭壞死保髖治療指南(2016版)[J].中華老年骨科與康復(fù)電子雜志,2016,2(2):65-70.
[2] CUI L,ZHUANG Q,LIN J,et al.Multicentric epidemiologic study on six thousand three hundred and ninety five cases of femoral head osteonecrosis in China[J].Int Orthop,2016,40(2):267-276.
[3] ZHAO D W,YU M,HU K,et al.Prevalence of Nontraumatic osteonecrosis of the femoral head and its associated risk factors in the Chinese population:results from a nationally representative survey[J].Chin Med J(Engl),2015,128(21):2843-2850.
[4] ZHANG Q,YANG F,CHEN Y,et al.Chinese herbal medicine formulas as adjuvant therapy for osteonecrosis of the femoral head:a systematic review and meta-analysis of randomized controlled trials [J].Medicine(Baltimore),2018,97(36):e12196.
[5] 陳雷雷,何偉,張慶文,等.中醫(yī)藥治療股骨頭壞死臨床試驗(yàn)的系統(tǒng)評(píng)價(jià)[J].中華中醫(yī)藥雜志,2012,27(3):710-715.
[6] 楊公博,朱立國(guó),何佩珊,等.中藥補(bǔ)腎活血湯治療老年腎虛型腰椎間盤(pán)突出癥的臨床研究[J].中華中醫(yī)藥雜志,2017,32(2):604-606.
[7] 何偉,陳鎮(zhèn)秋,張慶文.補(bǔ)腎活血中藥治療股骨頭壞死臨床研究[J].新中醫(yī),2012,44(4):50-51.
[8] 帥波,沈霖,楊艷萍,等.補(bǔ)腎活血方治療早期缺血性股骨頭壞死患者的臨床研究[J].中國(guó)中醫(yī)骨傷科雜志,2013,21(1):11-14.
[9] 張超,姚晨,沈計(jì)榮.微創(chuàng)髓芯減壓打壓支撐植骨術(shù)結(jié)合補(bǔ)腎活血湯口服治療ARCOⅡ、Ⅲ期股骨頭壞死的近期療效觀察[J].中醫(yī)正骨,2016,28(3):20-23.
[10] 姚晨,沈計(jì)榮,杜斌,等.口服補(bǔ)腎活血湯聯(lián)合微創(chuàng)保髖術(shù)治療股骨頭壞死腎虛血瘀證的臨床研究[J].中醫(yī)正骨,2016,28(11):7-12.
[11] 夏天衛(wèi),劉金柱,施樂(lè),等.補(bǔ)腎活血湯治療早期股骨頭壞死的癥狀轉(zhuǎn)歸及作用機(jī)制分析[J].中外醫(yī)學(xué)研究,2019,17(22):47-49.
[12] 魏偉,沈計(jì)榮,姚晨,等.旋轉(zhuǎn)截骨術(shù)配合口服補(bǔ)腎活血湯治療中青年ARCO Ⅲ期股骨頭骨壞死的近期療效[J].世界中醫(yī)藥,2019,14(4):936-940.
[13] 李業(yè)清.髖關(guān)節(jié)外科脫位死骨清理打壓植骨聯(lián)合補(bǔ)腎活血湯治療股骨頭壞死ARCOⅢ_A～Ⅲ_B期臨床研究[D].南京:南京中醫(yī)藥大學(xué),2017.
[14] 許芝俊.打壓植骨術(shù)聯(lián)合補(bǔ)腎活血湯治療股骨頭壞死的臨床研究[D].南京:南京中醫(yī)藥大學(xué),2016.
[15] 劉志華,孫曉波.網(wǎng)絡(luò)藥理學(xué):中醫(yī)藥現(xiàn)代化的新機(jī)遇[J].藥學(xué)學(xué)報(bào),2012,47(6):696-703.
[16] LIU C X,LIU R,FAN H R,et al.Network pharmacology bridges traditional applicatio n and modern development of traditional Chinese medicine[J].Chin Herb Med,2015,7(1):3-17.
[17] 謝盈彧,劉璐,李淵芳,等.基于網(wǎng)絡(luò)藥理學(xué)的四妙勇安湯在血管新生中的作用機(jī)制研究[J].中草藥,2018,49(18):4319-4330.
[18] 劉艷飛,孫明月,趙瑩科,等.網(wǎng)絡(luò)藥理學(xué)在中藥藥物重定位研究中的應(yīng)用現(xiàn)狀與思考[J].中國(guó)循證醫(yī)學(xué)雜志,2017,17(11):1344-1349.
[19] 王琳珊,靳會(huì)欣,董占軍.系統(tǒng)藥理學(xué)研究方法在中藥不良反應(yīng)研究中的應(yīng)用進(jìn)展[J].中國(guó)藥房,2017,28(35):5033-5036.
[20] MUTHUKURU M,DARVEAU R P.TLR signaling that induces weak inflammatory response and SHIP1 enhances osteogenic functions[J].Bone Res,2014,2(4):218-230.
[21] HUANG R L,YUAN Y,ZOU G M,et al.LPS-stimulated inflammatory environment inhibits BMP-2-induced osteoblastic differentiation through crosstalk between TLR4/MyD88/NF-κB and BMP/Smad signaling[J].Stem Cells Dev,2014,23(3):277-289.
[22] PEI J,FAN L,NAN K,et al.Excessive activation of TLR4/NF-κB interactively suppresses the canonical Wnt/β-catenin pathway and induces SANFH in SD rats[J].Sci Rep,2017,7(1):11928.
[23] TIAN L,ZHOU D,WANG K,et al.Association of toll-like receptor 4 signaling pathway with steroid-induced femoral head osteonecrosis in rats[J].J Huazhong Univ Sci Technolog Med Sci,2014,34(5):679-686.
[24] WEINSTEIN R S,JILKA R L,ALMEIDA M,et al.Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability,bone formation,and strength in mice[J].Endocrinology,2010,151(6):2641-2649.
[25] TIANWEI XIA,JIRONG SHEN,RUNZI GAO,et al.Trans-cinnamaldehyde inhibits IL-1β-stimulated inflammation in chondrocytes by suppressing NF-κB and p38-JNK pathways and exerts chondrocyte protective effects in a rat model of osteoarthritis[J].Biomed Res Int,2019[2020-01-01].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530235/.
[26] HAN Y,JUNG H W,LEE J Y,et al.2,5-dihydroxyacetophenone isolated from rehmanniae radix preparata inhibits inflammatory responses in lipopolysaccharide-stimulated RAW264.7 macrophages[J].J Med Food,2012,15(6):505-510.
[27] WANG C,PENG J,LU S.Summary of the various treatments for osteonecrosis of the femoral head by mechanism:a review[J].Exp Ther Med,2014,8(3):700-706.
[28] WEI LI,ZILIANG YE,WEI WANG,et al.Clinical effect of hyperbaric oxygen therapy in the treatment of femoral head necrosis:a systematic review and meta-analysis[J].Orthopade,2016,46(5):440-446.
[29] TROUSDALE R T.Femoral Head resurfacing for the treatment of osteonecrosis in the young patient[J].Clin Orthop Relat Res,2004,425(417):290-291.
[30] GALE N W,YANCOPOULOS G D.Growth factors acting via endothelial cell-specific receptor tyrosine kinases:VEGFs,angiopoietins,and ephrins in vascular development[J].Genes Dev,1999,3(9):1055-1066.
[31] CHEN Y,MATHY N W,LU H.The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non?small cell lung cancer(Review)[J].Mol Med Rep,2018,17(6):8019-8030.
[32] LI W,SAKAI T,NISHII T,et al.Distribution of TRAP-positive cells and expression of HIF-1alpha,VEGF,and FGF-2 in the reparative reaction in patients with osteonecrosis of the femoral head[J].J Orthop Res,2009,27(5):694-700.
[33] HONG G J,LIN N,CHEN L L,et al.Association between vascular endothelial growth factor gene polymorphisms and the risk of osteonecrosis of the femoral head:systematic review[J].Biomed Rep,2016,4(1):92-96.
[34] HANG D,WANG Q,GUO C,et al.Treatment of osteonecrosis of the femoral head with VEGF165 transgenic bone marrow mesenchymal stem cells in mongrel dogs[J].Cells Tissues Organs,2012,195(6):495-506.
[35] GAO Y S,WANG H F,DING H,et al.A novel rat model of osteonecrosis of the femoral head induced by periarticular injection of vascular endothelial growth factor receptor 2 antibody[J].J Surg Res,2013,183(1):e1-e5.

相似文獻(xiàn)/References:

[1]陳雷雷,張穎.何偉教授采用中醫(yī)藥療法治療股骨頭壞死的經(jīng)驗(yàn)[J].中醫(yī)正骨,2015,27(10):74.
[2]徐西林,趙永蘭,張曉峰,等.活骨注射液髖關(guān)節(jié)腔灌注對(duì)兔股骨頭壞死模型 血管內(nèi)皮生長(zhǎng)因子表達(dá)的動(dòng)態(tài)影響[J].中醫(yī)正骨,2015,27(08):1.
　XU Xilin,ZHAO Yonglan,ZHANG Xiaofeng,et al.Dynamic effect of intra-articular hip injection of Huogu injection on the expression of vascular endothelial growth factor in rabbit models with femur head necrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):1.
[3]周勇,任菲菲,豐凡翔,等.血管內(nèi)皮生長(zhǎng)因子和骨形態(tài)發(fā)生蛋白2 在非創(chuàng)傷性股骨頭壞死不同區(qū)域的表達(dá)[J].中醫(yī)正骨,2015,27(08):7.
　ZHOU Yong,REN Feifei,FENG Fanxiang,et al.Expressions of vascular endothelial growth factor and bone morphogenetic protein 2 in different zones of femoral head with non-traumatic osteonecrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):7.
[4]鮑榮華,王國(guó)平,夏曉斌,等.鉭棒植入治療非創(chuàng)傷性股骨頭壞死的療效觀察[J].中醫(yī)正骨,2015,27(02):28.
[5]張兵,馬凰富,劉波,等.非創(chuàng)傷性股骨頭壞死的舌象定量研究[J].中醫(yī)正骨,2015,27(04):8.
　ZHANG Bing,MA Huangfu,LIU Bo,et al.Quantitative study on tongue manifestation of patients with nontraumatic osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):8.
[6]李剛,程春生.股骨頭壞死血瘀證癥狀與平樂(lè)郭氏正骨方藥藥物組成 最大頻繁關(guān)聯(lián)模式挖掘[J].中醫(yī)正骨,2015,27(04):21.
　LI Gang,CHENG Chunsheng.Maximal frequent association pattern mining for studying the relationship between BLOOD STASIS syndrome in patients with osteonecrosis of femoral head and drug components of Pingle Guo's orthopedics prescription[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):21.
[7]李文龍,梅沉成,杜貴強(qiáng),等.微創(chuàng)減壓植骨多孔鉭棒植入治療 ARCOⅡ期非創(chuàng)傷性缺血性股骨頭壞死[J].中醫(yī)正骨,2016,28(02):43.
[8]張磊,金紅婷,童培建.骨健口服液早期干預(yù)非創(chuàng)傷性股骨頭壞死的臨床研究[J].中醫(yī)正骨,2016,28(03):14.
　ZHANG Lei,JIN Hongting,TONG Peijian.Clinical study on Gujian Koufuye(骨健口服液)for early intervention of nontraumatic osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(03):14.
[9]鮑榮華,王國(guó)平,夏曉斌,等.直接前入路微創(chuàng)全髖關(guān)節(jié)置換術(shù)治療晚期股骨頭壞死[J].中醫(yī)正骨,2016,28(03):61.
[10]唐立明,龐智暉,樊粵光,等.“辨穩(wěn)論治”微觀辨證理念指導(dǎo)下的股骨頭壞死圍塌陷期分型及其臨床應(yīng)用價(jià)值[J].中醫(yī)正骨,2016,28(05):63.
[11]張超,姚晨,沈計(jì)榮.微創(chuàng)髓芯減壓打壓支撐植骨術(shù)結(jié)合補(bǔ)腎活血湯口服治療ARCOⅡ、Ⅲ期股骨頭壞死的近期療效觀察[J].中醫(yī)正骨,2016,28(03):20.
　ZHANG Chao,YAO Chen,SHEN Jirong.[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(03):20.
[12]姚晨,沈計(jì)榮,杜斌,等.口服補(bǔ)腎活血湯聯(lián)合微創(chuàng)保髖術(shù)治療股骨頭壞死腎虛血瘀證的臨床研究[J].中醫(yī)正骨,2016,28(11):7.
　YAO Chen,SHEN Jirong,DU Bin,et al.Clinical study on oral application of Bushen Huoxue Tang(補(bǔ)腎活血湯)combined with minimally invasive hip-preserving surgery for treatment of kidney-deficiency-blood-stasis-type osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(03):7.
[13]范奕松,俞桂松,唐振坤,等.補(bǔ)腎活血湯治療股骨頭壞死的系統(tǒng)評(píng)價(jià)[J].中醫(yī)正骨,2020,32(03):26.
　FAN Yisong,YU Guisong,TANG Zhenkun,et al.Systematic review on Bushen Huoxue Tang(補(bǔ)腎活血湯)for treatment of osteonecrosis of the femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2020,32(03):26.

備注/Memo

備注/Memo:
(收稿日期:2020-02-12 本文編輯:李曉樂(lè))通訊作者:沈計(jì)榮 E-mail:[email protected]
更新日期/Last Update: 2020-03-10